Published in Biochim Biophys Acta on February 11, 2008
Protection from obesity and diabetes by blockade of TGF-β/Smad3 signaling. Cell Metab (2011) 2.73
To build a synapse: signaling pathways in neuromuscular junction assembly. Development (2010) 2.65
The AOM/DSS murine model for the study of colon carcinogenesis: From pathways to diagnosis and therapy studies. J Carcinog (2011) 2.30
The pathophysiology of epithelial-mesenchymal transition induced by transforming growth factor-beta in normal and malignant mammary epithelial cells. J Mammary Gland Biol Neoplasia (2010) 2.12
Extracellular matrix molecules: potential targets in pharmacotherapy. Pharmacol Rev (2009) 1.90
Arrestin development: emerging roles for beta-arrestins in developmental signaling pathways. Dev Cell (2009) 1.83
Transforming growth factor beta as a therapeutic target in systemic sclerosis. Nat Rev Rheumatol (2009) 1.79
ADAMTSL2 mutations in geleophysic dysplasia demonstrate a role for ADAMTS-like proteins in TGF-beta bioavailability regulation. Nat Genet (2008) 1.78
Cox-2 inactivates Smad signaling and enhances EMT stimulated by TGF-beta through a PGE2-dependent mechanisms. Carcinogenesis (2008) 1.69
Altered TGF-β signaling in a subpopulation of human stromal cells promotes prostatic carcinogenesis. Cancer Res (2011) 1.62
Targeting the transforming growth factor-beta signaling pathway in human cancer. Expert Opin Investig Drugs (2010) 1.57
Dynamical and structural analysis of a T cell survival network identifies novel candidate therapeutic targets for large granular lymphocyte leukemia. PLoS Comput Biol (2011) 1.51
Roles for the type III TGF-beta receptor in human cancer. Cell Signal (2010) 1.50
Transforming growth factor-β: activation by neuraminidase and role in highly pathogenic H5N1 influenza pathogenesis. PLoS Pathog (2010) 1.44
Clinical development of galunisertib (LY2157299 monohydrate), a small molecule inhibitor of transforming growth factor-beta signaling pathway. Drug Des Devel Ther (2015) 1.33
A rapid and sensitive bioassay for the simultaneous measurement of multiple bone morphogenetic proteins. Identification and quantification of BMP4, BMP6 and BMP9 in bovine and human serum. BMC Cell Biol (2009) 1.30
Role of TGF-β signaling in inherited and acquired myopathies. Skelet Muscle (2011) 1.28
Integrin-mediated transforming growth factor-beta activation, a potential therapeutic target in fibrogenic disorders. Am J Pathol (2009) 1.25
A systematic analysis of the skeletal muscle miRNA transcriptome of chicken varieties with divergent skeletal muscle growth identifies novel miRNAs and differentially expressed miRNAs. BMC Genomics (2011) 1.20
Expression of nodal signalling components in cycling human endometrium and in endometrial cancer. Reprod Biol Endocrinol (2009) 1.18
Sequential activation of NFAT and c-Myc transcription factors mediates the TGF-beta switch from a suppressor to a promoter of cancer cell proliferation. J Biol Chem (2010) 1.15
Transforming growth factor-(beta)s and mammary gland involution; functional roles and implications for cancer progression. J Mammary Gland Biol Neoplasia (2009) 1.15
Genetic variation in the TGF-β signaling pathway and colon and rectal cancer risk. Cancer Epidemiol Biomarkers Prev (2010) 1.15
Autocrine bone morphogenetic protein-9 signals through activin receptor-like kinase-2/Smad1/Smad4 to promote ovarian cancer cell proliferation. Cancer Res (2009) 1.14
Associations between genetic variation in RUNX1, RUNX2, RUNX3, MAPK1 and eIF4E and riskof colon and rectal cancer: additional support for a TGF-β-signaling pathway. Carcinogenesis (2010) 1.11
PDP-1 links the TGF-β and IIS pathways to regulate longevity, development, and metabolism. PLoS Genet (2011) 1.10
Transforming growth factor beta signaling in adult cardiovascular diseases and repair. Cell Tissue Res (2011) 1.10
Endocytosis of the type III transforming growth factor-beta (TGF-beta) receptor through the clathrin-independent/lipid raft pathway regulates TGF-beta signaling and receptor down-regulation. J Biol Chem (2008) 1.09
Regulation of TGF-beta signalling by protein phosphatases. Biochem J (2010) 1.08
Post-transcriptional regulation of Transforming Growth Factor Beta-1 by microRNA-744. PLoS One (2011) 1.05
Tumor angiogenesis: insights and innovations. J Oncol (2010) 1.04
Identification of novel pathways involved in the pathogenesis of human adamantinomatous craniopharyngioma. Acta Neuropathol (2012) 1.04
TGF-β signaling and the development of osteoarthritis. Bone Res (2014) 1.03
Transforming growth factor-beta and matrix metalloproteinases: functional interactions in tumor stroma-infiltrating myeloid cells. ScientificWorldJournal (2014) 1.03
The type III transforming growth factor-beta receptor negatively regulates nuclear factor kappa B signaling through its interaction with beta-arrestin2. Carcinogenesis (2009) 1.02
The type III TGF-beta receptor suppresses breast cancer progression through GIPC-mediated inhibition of TGF-beta signaling. Carcinogenesis (2009) 1.02
Transforming growth factor beta1 inhibits cystic fibrosis transmembrane conductance regulator-dependent cAMP-stimulated alveolar epithelial fluid transport via a phosphatidylinositol 3-kinase-dependent mechanism. J Biol Chem (2009) 1.02
Proto-oncogenic isoform A2 of eukaryotic translation elongation factor eEF1 is a target of miR-663 and miR-744. Br J Cancer (2013) 1.01
Two distinct regions of latency-associated peptide coordinate stability of the latent transforming growth factor-beta1 complex. J Biol Chem (2010) 0.99
X-linked inhibitor of apoptosis protein and its E3 ligase activity promote transforming growth factor-{beta}-mediated nuclear factor-{kappa}B activation during breast cancer progression. J Biol Chem (2009) 0.98
Antitransforming growth factor-beta therapy in fibrosis: recent progress and implications for systemic sclerosis. Curr Opin Rheumatol (2008) 0.97
Caenorhabditis elegans SMA-10/LRIG is a conserved transmembrane protein that enhances bone morphogenetic protein signaling. PLoS Genet (2010) 0.96
Requirement of TCF7L2 for TGF-beta-dependent transcriptional activation of the TMEPAI gene. J Biol Chem (2010) 0.96
BMP2 signals loss of epithelial character in epicardial cells but requires the Type III TGFβ receptor to promote invasion. Cell Signal (2012) 0.95
The transforming growth factor-beta type III receptor mediates distinct subcellular trafficking and downstream signaling of activin-like kinase (ALK)3 and ALK6 receptors. Mol Biol Cell (2009) 0.92
Stabilization of perturbed Boolean network attractors through compensatory interactions. BMC Syst Biol (2014) 0.91
Abrogated transforming growth factor beta receptor II (TGFβRII) signalling in dendritic cells promotes immune reactivity of T cells resulting in enhanced atherosclerosis. Eur Heart J (2012) 0.91
Transforming Growth Factor-Beta and Oxidative Stress Interplay: Implications in Tumorigenesis and Cancer Progression. Oxid Med Cell Longev (2015) 0.91
Getting 'Smad' about obesity and diabetes. Nutr Diabetes (2012) 0.90
A conserved stem loop motif in the 5'untranslated region regulates transforming growth factor-β(1) translation. PLoS One (2010) 0.90
Evaluation of safety, pharmacokinetics, and efficacy of vorinostat, a histone deacetylase inhibitor, in the treatment of gastrointestinal (GI) cancer in a phase I clinical trial. Int J Clin Oncol (2012) 0.88
Genetic variation in the transforming growth factor-β signaling pathway and survival after diagnosis with colon and rectal cancer. Cancer (2011) 0.88
The RGM protein DRAG-1 positively regulates a BMP-like signaling pathway in Caenorhabditis elegans. Development (2010) 0.87
Genetic defects of GDF6 in the zebrafish out of sight mutant and in human eye developmental anomalies. BMC Genet (2010) 0.87
The Role of TGF-β Receptors in Fibrosis. Open Rheumatol J (2012) 0.87
Transforming growth factor beta 1 (TGF-beta 1) in atrial fibrillation and acute congestive heart failure. Clin Res Cardiol (2010) 0.87
Endocardial cell epithelial-mesenchymal transformation requires Type III TGFβ receptor interaction with GIPC. Cell Signal (2011) 0.87
The influence of genetic ancestry and ethnicity on breast cancer survival associated with genetic variation in the TGF-β-signaling pathway: The Breast Cancer Health Disparities Study. Cancer Causes Control (2013) 0.86
Genetic variation in the transforming growth factor-β-signaling pathway, lifestyle factors, and risk of colon or rectal cancer. Dis Colon Rectum (2012) 0.86
A systematic experimental evaluation of microRNA markers of human bladder cancer. Front Genet (2013) 0.86
Transforming Growth Factor-β1 as a Common Target Molecule for Development of Cardiovascular Diseases, Renal Insufficiency and Metabolic Syndrome. Cardiol Res Pract (2010) 0.86
Increased expression of collagens, transforming growth factor-beta1, and -beta3 in gluteal muscle contracture. BMC Musculoskelet Disord (2010) 0.86
Signal molecule-mediated hepatic cell communication during liver regeneration. World J Gastroenterol (2009) 0.85
Inhibition of TGF-β signaling, vasculogenic mimicry and proinflammatory gene expression by isoxanthohumol. Invest New Drugs (2011) 0.85
TGFβ signaling in cartilage development and maintenance. Birth Defects Res C Embryo Today (2014) 0.85
Transforming growth factor β as regulator of cancer stemness and metastasis. Br J Cancer (2016) 0.85
Gene expression profiling reveals Cyp26b1 to be an activin regulated gene involved in ovarian granulosa cell proliferation. Endocrinology (2010) 0.85
The anti-proliferative function of the TGF-β1 signaling pathway involves the repression of the oncogenic TBX2 by its homologue TBX3. J Biol Chem (2014) 0.84
Some perspectives on network modeling in therapeutic target prediction. Biomed Eng Comput Biol (2013) 0.84
BMP-2 and TGF-β3 do not prevent spontaneous degeneration in rabbit disc explants but induce ossification of the annulus fibrosus. Eur Spine J (2012) 0.84
Progressive aortic dilation and aortic stiffness in children with repaired tetralogy of Fallot. Heart Vessels (2013) 0.83
Mechanistic relationship between membrane type-1 matrix metalloproteinase and the myocardial response to pressure overload. Circ Heart Fail (2014) 0.83
Dab2 inhibits the cholesterol-dependent activation of JNK by TGF-β. Mol Biol Cell (2014) 0.83
Coated pit-mediated endocytosis of the type I transforming growth factor-β (TGF-β) receptor depends on a di-leucine family signal and is not required for signaling. J Biol Chem (2012) 0.83
Repulsive guidance molecules (RGMs) and neogenin in bone morphogenetic protein (BMP) signaling. Mol Reprod Dev (2013) 0.82
C18 ORF1, a novel negative regulator of transforming growth factor-β signaling. J Biol Chem (2014) 0.82
Association between TGFBR1 polymorphisms and cancer risk: a meta-analysis of 35 case-control studies. PLoS One (2012) 0.82
Masking epistasis between MYC and TGF-β pathways in antiangiogenesis-mediated colon cancer suppression. J Natl Cancer Inst (2014) 0.82
Prostaglandin (PG)E2 exhibits antifibrotic activity in vocal fold fibroblasts. Laryngoscope (2011) 0.82
Changes of T-lymphocyte subpopulation and differential expression pattern of the T-bet and GATA-3 genes in diffuse large B-cell lymphoma patients after chemotherapy. Cancer Cell Int (2014) 0.81
Mkk4 is a negative regulator of the transforming growth factor beta 1 signaling associated with atrial remodeling and arrhythmogenesis with age. J Am Heart Assoc (2014) 0.81
Urinary transforming growth factor beta-1 as a marker of renal dysfunction in sickle cell disease. Pediatr Nephrol (2010) 0.81
Comparison of transforming growth factor beta expression in healthy and diseased human tendon. Arthritis Res Ther (2016) 0.81
A pathway approach to evaluating the association between the CHIEF pathway and risk of colorectal cancer. Carcinogenesis (2014) 0.81
Regulation of transforming growth factor-beta-dependent cyclooxygenase-2 expression in fibroblasts. J Biol Chem (2009) 0.81
Collagen metabolic disorder induced by oxidative stress in human uterosacral ligament‑derived fibroblasts: A possible pathophysiological mechanism in pelvic organ prolapse. Mol Med Rep (2016) 0.81
Gene expression signature of c-MYC-immortalized human fibroblasts reveals loss of growth inhibitory response to TGFβ. Cell Cycle (2011) 0.80
Computational modelling of Smad-mediated negative feedback and crosstalk in the TGF-β superfamily network. J R Soc Interface (2013) 0.80
ACVR1 p.Q207E causes classic fibrodysplasia ossificans progressiva and is functionally distinct from the engineered constitutively active ACVR1 p.Q207D variant. Hum Mol Genet (2014) 0.80
The neogenin/DCC homolog UNC-40 promotes BMP signaling via the RGM protein DRAG-1 in C. elegans. Development (2013) 0.79
Fine-tuning of Smad protein function by poly(ADP-ribose) polymerases and poly(ADP-ribose) glycohydrolase during transforming growth factor β signaling. PLoS One (2014) 0.79
Inflammation induced loss of skeletal muscle. Bone (2015) 0.79
Neutrophilic Lung Inflammation Suppressed by Picroside II Is Associated with TGF-β Signaling. Evid Based Complement Alternat Med (2015) 0.79
Systemic administration of follistatin288 increases muscle mass and reduces fat accumulation in mice. Sci Rep (2013) 0.79
Increased Expression of TGFβR2 Is Associated with the Clinical Outcome of Non-Small Cell Lung Cancer Patients Treated with Chemotherapy. PLoS One (2015) 0.79
Tight junction protein 1 is regulated by transforming growth factor-β and contributes to cell motility in NSCLC cells. BMB Rep (2015) 0.78
Notch: A multi-functional integrating system of microenvironmental signals. Dev Biol (2016) 0.78
TGFβ signaling induces expression of Gadd45b in retinal ganglion cells. Invest Ophthalmol Vis Sci (2013) 0.78
Embryonic Lethality Due to Arrested Cardiac Development in Psip1/Hdgfrp2 Double-Deficient Mice. PLoS One (2015) 0.78
Investigating the mechanism of hepatocellular carcinoma progression by constructing genetic and epigenetic networks using NGS data identification and big database mining method. Oncotarget (2016) 0.78
Development of human protein reference database as an initial platform for approaching systems biology in humans. Genome Res (2003) 14.79
Role of transforming growth factor Beta in human cancer. J Clin Oncol (2005) 3.53
Mechanical stiffness grades metastatic potential in patient tumor cells and in cancer cell lines. Cancer Res (2011) 2.32
Beta-arrestin 2 mediates endocytosis of type III TGF-beta receptor and down-regulation of its signaling. Science (2003) 2.31
Deep sequencing of the small RNA transcriptome of normal and malignant human B cells identifies hundreds of novel microRNAs. Blood (2010) 2.15
The type III TGF-beta receptor suppresses breast cancer progression. J Clin Invest (2006) 2.06
Bone morphogenetic proteins signal through the transforming growth factor-beta type III receptor. J Biol Chem (2008) 1.71
The type III transforming growth factor-beta receptor as a novel tumor suppressor gene in prostate cancer. Cancer Res (2007) 1.65
Context-specific effects of fibulin-5 (DANCE/EVEC) on cell proliferation, motility, and invasion. Fibulin-5 is induced by transforming growth factor-beta and affects protein kinase cascades. J Biol Chem (2002) 1.58
Loss of type III transforming growth factor beta receptor expression increases motility and invasiveness associated with epithelial to mesenchymal transition during pancreatic cancer progression. Carcinogenesis (2007) 1.51
Roles for the type III TGF-beta receptor in human cancer. Cell Signal (2010) 1.50
The type III TGF-beta receptor regulates epithelial and cancer cell migration through beta-arrestin2-mediated activation of Cdc42. Proc Natl Acad Sci U S A (2009) 1.49
Role of transforming growth factor-beta in hematologic malignancies. Blood (2006) 1.41
Loss of betaglycan expression in ovarian cancer: role in motility and invasion. Cancer Res (2007) 1.30
Bevacizumab, oxaliplatin, and capecitabine with radiation therapy in rectal cancer: Phase I trial results. Int J Radiat Oncol Biol Phys (2007) 1.28
TbetaRIII suppresses non-small cell lung cancer invasiveness and tumorigenicity. Carcinogenesis (2008) 1.28
Endoglin promotes transforming growth factor beta-mediated Smad 1/5/8 signaling and inhibits endothelial cell migration through its association with GIPC. J Biol Chem (2008) 1.27
Increased toxicity with gefitinib, capecitabine, and radiation therapy in pancreatic and rectal cancer: phase I trial results. J Clin Oncol (2006) 1.21
Bone morphogenetic proteins induce pancreatic cancer cell invasiveness through a Smad1-dependent mechanism that involves matrix metalloproteinase-2. Carcinogenesis (2008) 1.17
Gfi-1B controls human erythroid and megakaryocytic differentiation by regulating TGF-beta signaling at the bipotent erythro-megakaryocytic progenitor stage. Blood (2010) 1.16
The interaction of endoglin with beta-arrestin2 regulates transforming growth factor-beta-mediated ERK activation and migration in endothelial cells. J Biol Chem (2007) 1.12
Endocytosis of the type III transforming growth factor-beta (TGF-beta) receptor through the clathrin-independent/lipid raft pathway regulates TGF-beta signaling and receptor down-regulation. J Biol Chem (2008) 1.09
The type III TGF-beta receptor signals through both Smad3 and the p38 MAP kinase pathways to contribute to inhibition of cell proliferation. Carcinogenesis (2007) 1.06
A phase II trial of bevacizumab plus everolimus for patients with refractory metastatic colorectal cancer. Oncologist (2011) 1.05
Proteoglycan signaling co-receptors: roles in cell adhesion, migration and invasion. Cell Signal (2009) 1.04
Cell-surface co-receptors: emerging roles in signaling and human disease. Trends Biochem Sci (2005) 1.02
ALK5 phosphorylation of the endoglin cytoplasmic domain regulates Smad1/5/8 signaling and endothelial cell migration. Carcinogenesis (2009) 1.02
The type III transforming growth factor-beta receptor negatively regulates nuclear factor kappa B signaling through its interaction with beta-arrestin2. Carcinogenesis (2009) 1.02
The type III TGF-beta receptor suppresses breast cancer progression through GIPC-mediated inhibition of TGF-beta signaling. Carcinogenesis (2009) 1.02
Type III TGF-β receptor downregulation generates an immunotolerant tumor microenvironment. J Clin Invest (2013) 1.02
Endoglin mediates fibronectin/α5β1 integrin and TGF-β pathway crosstalk in endothelial cells. EMBO J (2012) 1.02
Expression of the type III TGF-beta receptor is negatively regulated by TGF-beta. Carcinogenesis (2008) 0.99
Endoglin regulates PI3-kinase/Akt trafficking and signaling to alter endothelial capillary stability during angiogenesis. Mol Biol Cell (2012) 0.98
Type III TGF-β receptor enhances colon cancer cell migration and anchorage-independent growth. Neoplasia (2011) 0.96
A phase II study of capecitabine, oxaliplatin, bevacizumab and cetuximab in the treatment of metastatic colorectal cancer. Anticancer Res (2011) 0.95
Novel bone morphogenetic protein signaling through Smad2 and Smad3 to regulate cancer progression and development. FASEB J (2013) 0.95
The type III transforming growth factor-β receptor inhibits proliferation, migration, and adhesion in human myeloma cells. Mol Biol Cell (2011) 0.95
A phase I study of bevacizumab (B) in combination with everolimus (E) and erlotinib (E) in advanced cancer (BEE). Cancer Chemother Pharmacol (2010) 0.93
BMP-2 and TGFβ2 shared pathways regulate endocardial cell transformation. Cells Tissues Organs (2011) 0.93
Casein kinase 2beta as a novel enhancer of activin-like receptor-1 signaling. FASEB J (2009) 0.92
The transforming growth factor-beta type III receptor mediates distinct subcellular trafficking and downstream signaling of activin-like kinase (ALK)3 and ALK6 receptors. Mol Biol Cell (2009) 0.92
Molecular characterization of the tumor-suppressive function of nischarin in breast cancer. J Natl Cancer Inst (2011) 0.92
Safety, pharmacokinetics, pharmacodynamics, and antitumor activity of dalantercept, an activin receptor-like kinase-1 ligand trap, in patients with advanced cancer. Clin Cancer Res (2013) 0.91
Endocardial cell epithelial-mesenchymal transformation requires Type III TGFβ receptor interaction with GIPC. Cell Signal (2011) 0.87
Inhibiting the TGF-beta signalling pathway as a means of cancer immunotherapy. Expert Opin Biol Ther (2003) 0.87
A phase I study of bevacizumab, everolimus and panitumumab in advanced solid tumors. Cancer Chemother Pharmacol (2012) 0.86
A phase II study of oxaliplatin, dose-intense capecitabine, and high-dose bevacizumab in the treatment of metastatic colorectal cancer. Clin Colorectal Cancer (2011) 0.84
Phase I study of dasatinib in combination with capecitabine, oxaliplatin and bevacizumab followed by an expanded cohort in previously untreated metastatic colorectal cancer. Invest New Drugs (2013) 0.84
The type III TGFbeta receptor regulates directional migration: new tricks for an old dog. Cell Cycle (2009) 0.83
Effects of the combination of TRC105 and bevacizumab on endothelial cell biology. Invest New Drugs (2014) 0.82
A phase I study of ABT-510 plus bevacizumab in advanced solid tumors. Cancer Med (2013) 0.82
Regulation of ALK-1 signaling by the nuclear receptor LXRbeta. J Biol Chem (2002) 0.80
Type III TGF-β receptor promotes FGF2-mediated neuronal differentiation in neuroblastoma. J Clin Invest (2013) 0.80
A phase I dose-escalation study of imatinib mesylate (Gleevec/STI571) plus capecitabine (Xeloda) in advanced solid tumors. Anticancer Res (2010) 0.80
Stromal heparan sulfate differentiates neuroblasts to suppress neuroblastoma growth. J Clin Invest (2014) 0.78
A phase II study of capecitabine, oxaliplatin, and bevacizumab in the treatment of metastatic esophagogastric adenocarcinomas. Oncologist (2013) 0.78
Erratum to: angiotensin II stimulates canonical TGF-β signaling pathway through angiotensin type 1 receptor to induce granulation tissue contraction. J Mol Med (Berl) (2015) 0.77
The type III TGFβ receptor regulates filopodia formation via a Cdc42-mediated IRSp53-N-WASP interaction in epithelial cells. Biochem J (2013) 0.77
Angiotensin II stimulates canonical TGF-β signaling pathway through angiotensin type 1 receptor to induce granulation tissue contraction. J Mol Med (Berl) (2014) 0.76
A Phase I study of capecitabine, carboplatin, and paclitaxel with external beam radiation therapy for esophageal carcinoma. Int J Radiat Oncol Biol Phys (2006) 0.75